RU2469044C2 - Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1 - Google Patents
Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1 Download PDFInfo
- Publication number
- RU2469044C2 RU2469044C2 RU2009118432/10A RU2009118432A RU2469044C2 RU 2469044 C2 RU2469044 C2 RU 2469044C2 RU 2009118432/10 A RU2009118432/10 A RU 2009118432/10A RU 2009118432 A RU2009118432 A RU 2009118432A RU 2469044 C2 RU2469044 C2 RU 2469044C2
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- cells
- depdc1
- seq
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 350
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 192
- 206010028980 Neoplasm Diseases 0.000 title claims description 161
- 201000011510 cancer Diseases 0.000 title claims description 112
- 229920001184 polypeptide Polymers 0.000 title description 22
- 229940023041 peptide vaccine Drugs 0.000 title description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 275
- 238000000034 method Methods 0.000 claims abstract description 104
- 230000014509 gene expression Effects 0.000 claims abstract description 79
- 150000001413 amino acids Chemical class 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims abstract description 49
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 48
- 230000001939 inductive effect Effects 0.000 claims abstract description 40
- 229960005486 vaccine Drugs 0.000 claims abstract description 37
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 36
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 23
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 6
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 6
- 239000002157 polynucleotide Substances 0.000 claims abstract description 6
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 186
- 229940024606 amino acid Drugs 0.000 claims description 51
- 206010005003 Bladder cancer Diseases 0.000 claims description 44
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 44
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 44
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 43
- 239000000427 antigen Substances 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims description 26
- 206010006187 Breast cancer Diseases 0.000 claims description 24
- 208000026310 Breast neoplasm Diseases 0.000 claims description 24
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 24
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 24
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 24
- 206010025323 Lymphomas Diseases 0.000 claims description 24
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 24
- 201000010881 cervical cancer Diseases 0.000 claims description 24
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 24
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 24
- 201000008968 osteosarcoma Diseases 0.000 claims description 24
- 206010009944 Colon cancer Diseases 0.000 claims description 23
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 23
- 206010060862 Prostate cancer Diseases 0.000 claims description 22
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 21
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 21
- 206010017758 gastric cancer Diseases 0.000 claims description 21
- 201000011549 stomach cancer Diseases 0.000 claims description 21
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 20
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 210000004881 tumor cell Anatomy 0.000 claims description 20
- 206010038389 Renal cancer Diseases 0.000 claims description 18
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 18
- 201000010174 renal carcinoma Diseases 0.000 claims description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 14
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- 229930182817 methionine Natural products 0.000 claims description 10
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 96
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 23
- 239000000126 substance Substances 0.000 abstract description 4
- 101000950642 Homo sapiens DEP domain-containing protein 1A Proteins 0.000 description 144
- 102100037753 DEP domain-containing protein 1A Human genes 0.000 description 137
- 101001027631 Homo sapiens Kinesin-like protein KIF20B Proteins 0.000 description 119
- 102100037691 Kinesin-like protein KIF20B Human genes 0.000 description 119
- 102100037850 Interferon gamma Human genes 0.000 description 63
- 108010074328 Interferon-gamma Proteins 0.000 description 63
- 238000004519 manufacturing process Methods 0.000 description 50
- 102000011786 HLA-A Antigens Human genes 0.000 description 44
- 108010075704 HLA-A Antigens Proteins 0.000 description 44
- 230000004044 response Effects 0.000 description 28
- 230000006698 induction Effects 0.000 description 27
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 26
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 23
- 238000002255 vaccination Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000002163 immunogen Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 238000012549 training Methods 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 210000001808 exosome Anatomy 0.000 description 10
- 230000000644 propagated effect Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000010638 Kinesin Human genes 0.000 description 6
- 108010063296 Kinesin Proteins 0.000 description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 206010038038 rectal cancer Diseases 0.000 description 6
- 201000001275 rectum cancer Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 101100162703 Caenorhabditis elegans ani-1 gene Proteins 0.000 description 4
- 101100277553 Caenorhabditis elegans dep-1 gene Proteins 0.000 description 4
- 102000011087 DEP domains Human genes 0.000 description 4
- 108050001299 DEP domains Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 238000011254 conventional chemotherapy Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 150000002632 lipids Chemical group 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 101100011364 Caenorhabditis elegans egl-10 gene Proteins 0.000 description 2
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000017944 Dishevelled Human genes 0.000 description 2
- 108050007016 Dishevelled Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000031016 anaphase Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000016853 telophase Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 101150054188 DEPDC1 gene Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85257506P | 2006-10-17 | 2006-10-17 | |
| US60/852,575 | 2006-10-17 | ||
| PCT/JP2007/001122 WO2008047473A1 (en) | 2006-10-17 | 2007-10-16 | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009118432A RU2009118432A (ru) | 2010-11-27 |
| RU2469044C2 true RU2469044C2 (ru) | 2012-12-10 |
Family
ID=39313729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009118432/10A RU2469044C2 (ru) | 2006-10-17 | 2007-10-16 | Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8557955B2 (enExample) |
| EP (7) | EP2687540A1 (enExample) |
| JP (2) | JP5339292B2 (enExample) |
| KR (4) | KR101527473B1 (enExample) |
| CN (5) | CN101568550B (enExample) |
| AU (1) | AU2007311395B2 (enExample) |
| BR (1) | BRPI0717651A2 (enExample) |
| CA (2) | CA2915560A1 (enExample) |
| DK (1) | DK2091965T3 (enExample) |
| ES (4) | ES2545457T3 (enExample) |
| IL (4) | IL198186A (enExample) |
| MX (1) | MX2009004147A (enExample) |
| PL (1) | PL2091965T3 (enExample) |
| PT (1) | PT2091965E (enExample) |
| RU (1) | RU2469044C2 (enExample) |
| SG (2) | SG10201502098YA (enExample) |
| WO (1) | WO2008047473A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2760984C1 (ru) * | 2017-12-13 | 2021-12-02 | Иновио Фармасьютикалз, Инк. | Противораковые вакцины, направленные на lemd1, и их применение |
| US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| US11274278B2 (en) | 2014-04-16 | 2022-03-15 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| RU2778411C2 (ru) * | 2015-10-22 | 2022-08-18 | Джуно Терапьютикс Гмбх | Способы культивирования клеток и наборы и устройство для них |
| US11466253B2 (en) | 2015-10-22 | 2022-10-11 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US11866465B2 (en) | 2017-04-27 | 2024-01-09 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| US11913024B2 (en) | 2015-10-22 | 2024-02-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US12066365B2 (en) | 2012-02-23 | 2024-08-20 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| US12516099B2 (en) | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| US12522660B2 (en) | 2018-10-31 | 2026-01-13 | C3S2 Gmbh | Methods for selection and stimulation of cells and apparatus for same |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5109131B2 (ja) | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| US8455444B2 (en) * | 2007-08-20 | 2013-06-04 | Oncotherapy Science, Inc. | CDH3 peptide and medicinal agent comprising the same |
| EP2362904B1 (en) * | 2008-08-28 | 2016-11-16 | Oncotherapy Science, Inc. | Method of screening compounds for use in inhibiting depdc1 - znf224 binding |
| WO2010100878A1 (en) * | 2009-03-04 | 2010-09-10 | Oncotherapy Science, Inc. | Vangl1 peptides and vaccines including the same |
| WO2012032763A1 (en) * | 2010-09-07 | 2012-03-15 | Oncotherapy Science, Inc. | Vangl1 peptides and vaccines including the same |
| KR102015648B1 (ko) * | 2011-08-12 | 2019-08-28 | 온코세라피 사이언스 가부시키가이샤 | Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신 |
| JP2013058294A (ja) * | 2011-09-09 | 2013-03-28 | Toshiba Corp | 磁気記録媒体及び磁気記録媒体の製造方法 |
| US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
| JP6041297B2 (ja) * | 2012-08-24 | 2016-12-07 | 国立大学法人山口大学 | 犬リンパ腫の診断方法及び診断キット |
| CA2904802C (en) * | 2013-03-13 | 2021-03-30 | Zhong Li | Microvesicle and method for producing the same |
| US10537626B2 (en) | 2014-10-07 | 2020-01-21 | Cytlimic Inc. | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell |
| EP3207936B1 (en) * | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| JP6898225B2 (ja) | 2015-03-09 | 2021-07-07 | サイトリミック株式会社 | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| EP3797794A1 (en) | 2015-04-07 | 2021-03-31 | Cytlimic Inc. | Medicine comprising a toll like receptor 3 agonist and a lag-3 protein |
| AU2016306527B2 (en) * | 2015-08-12 | 2022-03-17 | Oncotherapy Science, Inc. | DEPDC1-derived peptide and vaccine containing same |
| HK1251928A1 (en) * | 2015-10-08 | 2019-05-03 | Oncotherapy Science, Inc. | MPHOSPH1-derived peptides and vaccines including it |
| AU2017342189B2 (en) | 2016-10-11 | 2023-09-21 | Nec Corporation | Medicine |
| WO2018092755A1 (en) * | 2016-11-18 | 2018-05-24 | Oncotherapy Science, Inc. | Mphosph1 epitope peptides for th1 cells and vaccines containing the same |
| JP2019535270A (ja) * | 2016-11-18 | 2019-12-12 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のためのＤＥＰＤＣ１エピトープペプチドおよびこれを含有するワクチン |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| MX2019008878A (es) | 2017-01-25 | 2020-02-13 | Ose Immunotherapeutics | Metodo para fabricar una emulsion estable para suministro de peptidos. |
| SG11202000250PA (en) * | 2017-07-12 | 2020-02-27 | Nouscom Ag | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers |
| CN109932510B (zh) * | 2017-12-18 | 2022-07-12 | 天津云检医学检验所有限公司 | 一种宫颈癌生物标志物及其检测试剂盒 |
| CN112142824B (zh) * | 2019-06-27 | 2022-03-11 | 深圳市东贵博康生化科技有限公司 | 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用 |
| WO2021060343A1 (ja) * | 2019-09-24 | 2021-04-01 | オンコセラピー・サイエンス株式会社 | Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体 |
| CN116368570A (zh) * | 2020-10-15 | 2023-06-30 | 米尼奥公司 | 用于确定肽免疫原性的方法、系统和计算机程序产品 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU94038427A (ru) * | 1991-08-26 | 1996-10-20 | Сайтел Корпорейшн (US) | Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации |
| WO2003040165A2 (en) * | 2000-10-19 | 2003-05-15 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
| WO2006085684A2 (en) * | 2005-02-10 | 2006-08-17 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JP3738395B2 (ja) | 1991-08-26 | 2006-01-25 | エピミューン，インコーポレイティド | Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ |
| AU678225B2 (en) * | 1993-03-11 | 1997-05-22 | University Of Southern California | Therapeutic strategies for immunoinfective cluster virus infections |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| CA2225553A1 (en) | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US7001999B1 (en) * | 1998-04-15 | 2006-02-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
| PL201881B1 (pl) * | 1998-09-30 | 2009-05-29 | Corixa Corp | Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd |
| US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US20040241726A1 (en) * | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of allergies related gene transcripts in blood |
| US6291663B1 (en) * | 1999-03-03 | 2001-09-18 | Board Of Trustees Of The University Of Arkansas | TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma |
| US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| JP2003518364A (ja) * | 1999-05-28 | 2003-06-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用 |
| CA2420543C (en) | 2000-08-22 | 2013-04-02 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| AU2001296235A1 (en) | 2000-10-12 | 2002-04-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP1356048A2 (en) * | 2000-12-04 | 2003-10-29 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2005515779A (ja) * | 2002-01-31 | 2005-06-02 | ワイス | アグレカナーゼ分子 |
| AU2003222103A1 (en) | 2002-03-28 | 2003-10-13 | Idec Pharmaceuticals Corporation | Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| WO2005007090A2 (en) | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| JP2006302684A (ja) | 2005-04-21 | 2006-11-02 | D D K Ltd | カードコネクタ |
| EP2295570A1 (en) * | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| US20070099251A1 (en) * | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| TWM336439U (en) * | 2008-02-14 | 2008-07-11 | Optivision Technology Inc | Diffuser capable of light condensing |
| EP2362904B1 (en) * | 2008-08-28 | 2016-11-16 | Oncotherapy Science, Inc. | Method of screening compounds for use in inhibiting depdc1 - znf224 binding |
| KR102015648B1 (ko) | 2011-08-12 | 2019-08-28 | 온코세라피 사이언스 가부시키가이샤 | Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신 |
-
2007
- 2007-10-16 EP EP20130189390 patent/EP2687540A1/en not_active Withdrawn
- 2007-10-16 MX MX2009004147A patent/MX2009004147A/es active IP Right Grant
- 2007-10-16 AU AU2007311395A patent/AU2007311395B2/en not_active Ceased
- 2007-10-16 EP EP20130189408 patent/EP2687541A1/en not_active Withdrawn
- 2007-10-16 SG SG10201502098YA patent/SG10201502098YA/en unknown
- 2007-10-16 EP EP12155444.8A patent/EP2476697B1/en active Active
- 2007-10-16 SG SG2011070455A patent/SG175566A1/en unknown
- 2007-10-16 BR BRPI0717651-1A2A patent/BRPI0717651A2/pt not_active IP Right Cessation
- 2007-10-16 KR KR1020157000123A patent/KR101527473B1/ko active Active
- 2007-10-16 CN CN2007800467286A patent/CN101568550B/zh active Active
- 2007-10-16 EP EP20130189400 patent/EP2695895A1/en not_active Withdrawn
- 2007-10-16 KR KR1020147011020A patent/KR101493773B1/ko active Active
- 2007-10-16 PT PT78279015T patent/PT2091965E/pt unknown
- 2007-10-16 PL PL07827901T patent/PL2091965T3/pl unknown
- 2007-10-16 RU RU2009118432/10A patent/RU2469044C2/ru not_active IP Right Cessation
- 2007-10-16 CN CN201210305732.2A patent/CN102850435B/zh active Active
- 2007-10-16 WO PCT/JP2007/001122 patent/WO2008047473A1/en not_active Ceased
- 2007-10-16 ES ES12155448.9T patent/ES2545457T3/es active Active
- 2007-10-16 DK DK07827901.5T patent/DK2091965T3/da active
- 2007-10-16 KR KR1020097010056A patent/KR101454287B1/ko active Active
- 2007-10-16 ES ES12155446.3T patent/ES2545818T3/es active Active
- 2007-10-16 US US12/445,729 patent/US8557955B2/en active Active
- 2007-10-16 ES ES07827901T patent/ES2415958T3/es active Active
- 2007-10-16 CA CA2915560A patent/CA2915560A1/en not_active Abandoned
- 2007-10-16 KR KR1020147022451A patent/KR101543622B1/ko active Active
- 2007-10-16 EP EP07827901.5A patent/EP2091965B9/en active Active
- 2007-10-16 CN CN201610069574.3A patent/CN105693843A/zh active Pending
- 2007-10-16 CN CN201210305211.7A patent/CN102850434B/zh active Active
- 2007-10-16 JP JP2009516776A patent/JP5339292B2/ja active Active
- 2007-10-16 CA CA2667030A patent/CA2667030C/en not_active Expired - Fee Related
- 2007-10-16 EP EP12155448.9A patent/EP2476699B1/en active Active
- 2007-10-16 ES ES12155444.8T patent/ES2545817T3/es active Active
- 2007-10-16 CN CN201210305207.0A patent/CN102850433B/zh active Active
- 2007-10-16 EP EP12155446.3A patent/EP2476698B1/en active Active
-
2009
- 2009-04-16 IL IL198186A patent/IL198186A/en not_active IP Right Cessation
-
2011
- 2011-12-01 IL IL216713A patent/IL216713A0/en unknown
- 2011-12-01 IL IL216712A patent/IL216712A/en not_active IP Right Cessation
-
2012
- 2012-06-27 US US13/535,297 patent/US9017688B2/en active Active
- 2012-06-27 US US13/535,303 patent/US8653234B2/en active Active
- 2012-07-30 US US13/562,250 patent/US8552146B2/en active Active
- 2012-11-08 IL IL222925A patent/IL222925A0/en unknown
-
2013
- 2013-01-18 JP JP2013006870A patent/JP2013116115A/ja active Pending
-
2015
- 2015-03-24 US US14/667,560 patent/US9545437B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU94038427A (ru) * | 1991-08-26 | 1996-10-20 | Сайтел Корпорейшн (US) | Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации |
| WO2003040165A2 (en) * | 2000-10-19 | 2003-05-15 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
| WO2006085684A2 (en) * | 2005-02-10 | 2006-08-17 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
Non-Patent Citations (3)
| Title |
|---|
| FERRIES Е. ет al. Identification of р53 peptides recognized by CD8+T lymphocytes from patients with bladder cancer // HUMAN IMMUNOLOGY. - 2001, v. 62, no. 8, p.791-798 * |
| FERRIES Е. ет al. Identification of р53 peptides recognized by CD8+T lymphocytes from patients with bladder cancer // HUMAN IMMUNOLOGY. - 2001, v. 62, no. 8, p.791-798, весь документ. ITO K. et al. Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer // INTERNATIONAL JOURNAL OF CANCER. - 2004, v. 108, no. 5, p.712-724, весь документ. * |
| ITO K. et al. Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer // INTERNATIONAL JOURNAL OF CANCER. - 2004, v. 108, no. 5, p.712-724 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12066365B2 (en) | 2012-02-23 | 2024-08-20 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| US12135265B2 (en) | 2012-02-23 | 2024-11-05 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| US11274278B2 (en) | 2014-04-16 | 2022-03-15 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| RU2778411C2 (ru) * | 2015-10-22 | 2022-08-18 | Джуно Терапьютикс Гмбх | Способы культивирования клеток и наборы и устройство для них |
| US11466253B2 (en) | 2015-10-22 | 2022-10-11 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US12129477B2 (en) | 2015-10-22 | 2024-10-29 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| US11913024B2 (en) | 2015-10-22 | 2024-02-27 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US11866465B2 (en) | 2017-04-27 | 2024-01-09 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| RU2760984C1 (ru) * | 2017-12-13 | 2021-12-02 | Иновио Фармасьютикалз, Инк. | Противораковые вакцины, направленные на lemd1, и их применение |
| US11338028B2 (en) | 2017-12-13 | 2022-05-24 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting LEMD1 and uses thereof |
| US12516099B2 (en) | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| US12522660B2 (en) | 2018-10-31 | 2026-01-13 | C3S2 Gmbh | Methods for selection and stimulation of cells and apparatus for same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5339292B2 (ja) | Ｍｐｈｏｓｐｈ１またはｄｅｐｄｃ１ポリペプチドを発現する癌に対するペプチドワクチン | |
| TWI610939B (zh) | 表現腫瘤相關抗原之癌症的胜肽疫苗 | |
| HK1131169B (en) | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides | |
| HK1171025B (en) | Peptide vaccines for cancers expressing depdc1 polypeptides | |
| HK1171026B (en) | Peptide vaccines for cancers expressing depdc1 polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171017 |